Amgen Inc.'s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.'s Praluent are still struggling to get off the ground – but there is hope ahead for the PCSK9 inhibitors in terms of better labeling and better positioning in treatment guidelines for cholesterol reduction due in early September.
In its July 31 second-quarter earnings release, Sanofi reported €42m ($50m) in sales for Praluent (alirocumab), following Amgen's report of $83m for Repatha (evolocumab) sales on July 25. (Also see...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?